Ardelyx, Inc. will discuss 2024 financial results and business updates in a conference call on February 20, 2025.
Quiver AI Summary
Ardelyx, Inc. has announced a conference call scheduled for February 20, 2025, at 8:00 a.m. Eastern Time, to discuss its financial results and provide a business update for the full year and fourth quarter of 2024. Those interested in participating can join by calling either a domestic or international number provided in the release, and the call will also be available for live streaming on Ardelyx's website, with a replay option for 30 days. Ardelyx, a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, has two approved commercial products for use in the U.S. and international agreements for the commercialization of its lead drug, tenapanor.
Potential Positives
- Announcement of a conference call for financial results and business updates indicates transparency and engagement with stakeholders.
- Highlighting two commercially approved products demonstrates the company's capability in successfully bringing innovative medicines to market.
- The international agreements for tenapanor signify the company’s global expansion efforts and potential for revenue growth.
- The submission of a New Drug Application for tenapanor in China indicates ongoing product development and market opportunities in new regions.
Potential Negatives
- Announcement of a conference call may indicate a need to address financial results and business updates, suggesting potential challenges within the company's financial performance or strategic direction.
- The focus on financial results and possible negative implications may create uncertainty and concern among investors regarding the company's future prospects.
- Strategic reliance on a single drug (tenapanor) for commercialization across multiple markets could pose significant risks if its performance does not meet expectations or faces regulatory challenges.
FAQ
When is Ardelyx's next conference call scheduled?
Ardelyx's next conference call is scheduled for Thursday, February 20, 2025, at 8:00 a.m. Eastern Time.
How can I participate in the Ardelyx conference call?
To participate, dial (877) 346-6112 for domestic calls or (848) 280-6350 for international calls.
Where can I find the live webcast of the conference call?
The live audio of the conference call will be available under the Investors section of Ardelyx's website at www.ardelyx.com.
Will the conference call be available for replay?
Yes, the conference call will be archived and available for replay for 30 days following the call.
What products does Ardelyx currently commercialize?
Ardelyx has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARDX Insider Trading Activity
$ARDX insiders have traded $ARDX stock on the open market 34 times in the past 6 months. Of those trades, 3 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- DAVID M MOTT has made 3 purchases buying 628,168 shares for an estimated $2,985,849 and 0 sales.
- MICHAEL RAAB (President & CEO) has made 0 purchases and 12 sales selling 237,843 shares for an estimated $1,304,105.
- DAVID P. ROSENBAUM (Chief Development Officer) has made 0 purchases and 10 sales selling 164,129 shares for an estimated $1,022,184.
- LAURA A WILLIAMS (Chief Medical Officer) has made 0 purchases and 2 sales selling 14,778 shares for an estimated $78,752.
- ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 14,135 shares for an estimated $75,325.
- JUSTIN A RENZ (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,549 shares for an estimated $56,214.
- ROBERT BLANKS (See Remarks) has made 0 purchases and 2 sales selling 9,910 shares for an estimated $52,809.
- ROBERT ORA FELSCH (See Remarks) sold 3,567 shares for an estimated $20,903
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARDX Hedge Fund Activity
We have seen 95 institutional investors add shares of $ARDX stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 4,419,443 shares (-17.0%) from their portfolio in Q3 2024, for an estimated $30,449,962
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 2,167,308 shares (-75.1%) from their portfolio in Q3 2024, for an estimated $14,932,752
- MACQUARIE GROUP LTD added 2,047,773 shares (+29.7%) to their portfolio in Q3 2024, for an estimated $14,109,155
- CITADEL ADVISORS LLC added 1,948,301 shares (+747.5%) to their portfolio in Q3 2024, for an estimated $13,423,793
- RUBRIC CAPITAL MANAGEMENT LP added 1,243,606 shares (+68.5%) to their portfolio in Q3 2024, for an estimated $8,568,445
- DEUTSCHE BANK AG\ removed 1,189,967 shares (-82.0%) from their portfolio in Q3 2024, for an estimated $8,198,872
- TWO SIGMA INVESTMENTS, LP removed 1,025,463 shares (-51.0%) from their portfolio in Q3 2024, for an estimated $7,065,440
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com . The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA
®
(tenapanor) and XPHOZAH
®
(tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL
®
(tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit
https://ardelyx.com/
and connect with us on
X (formerly known as Twitter)
,
LinkedIn
and
Facebook
.
Investor and Media Contacts:
Caitlin Lowie
[email protected]